Patents Assigned to Alkermes Controlled Therapeutics, Inc.
-
Publication number: 20040191324Abstract: Method and apparatus for preparing microparticles using liquid-liquid extraction. A first phase and a second phase are combined to form an emulsion. A portion of the second phase is separated from the emulsion (solvent rich), and the solvent is extracted from the separated second phase, which is then returned (solvent poor) to the emulsion. This process of separation of a solvent rich phase, extraction of solvent, and return of a solvent poor phase, is carried out until a selected level of solvent in the emulsion is achieved. Alternatively, the separated solvent rich phase is not returned to the emulsion, but replaced with another solution, such as an aqueous solution, that is free from solvent. The solvent is preferably extracted into an extraction liquid that functions as a “solvent sink” for the solvent.Type: ApplicationFiled: April 12, 2004Publication date: September 30, 2004Applicant: Alkermes Controlled Therapeutics Inc. IIInventor: J. Michael Ramstack
-
Patent number: 6780434Abstract: This invention relates to a composition, and method of forming said composition, for the controlled release of interferon. The controlled release composition of this invention comprises a biocompatible polymer and particles of metal cation-stabilized interferon, wherein the particles are dispersed within the biocompatible polymer. The method of the invention, for producing a composition for the controlled release of interferon, includes dissolving a polymer in a polymer solvent to form a polymer solution, dispersing particles of metal cation stabilized-interferon particles in the polymer solution, and then solidifying the polymer to form a polymeric matrix containing a dispersion of the interferon particles.Type: GrantFiled: March 6, 2002Date of Patent: August 24, 2004Assignee: Alkermes Controlled Therapeutics, Inc.Inventors: Mark A. Tracy, Howard Bernstein, M. Amin Khan
-
Publication number: 20040147488Abstract: The present invention relates to a method for the sustained release in vivo of a biologically active agent comprising administering to a subject in need of treatment an effective amount of a sustained release composition comprising a biocompatible polymer having the biologically active agent incorporated therein, and a bisphosphonate wherein the bisphosphonate compound is present in an amount sufficient to modify the release profile of the biologically active agent from the sustained release composition. Pharmaceutical compositions suitable for use in the method of the invention are also disclosed.Type: ApplicationFiled: January 16, 2004Publication date: July 29, 2004Applicant: Alkermes Controlled Therapeutics, Inc.Inventors: James R. Dasch, M. Gary I. Riley
-
Publication number: 20040121009Abstract: The present invention relates to a method for the sustained release in vivo of a biologically active labile agent comprising administering to a subject in need of treatment an effective amount of a sustained release composition comprising a biocompatible polymer having the biologically active labile agent incorporated therein, and a corticosteroid wherein the labile is released for a period of at least about two weeks. It is understood that the corticosteroid is present in an amount sufficient to modify the release profile of the biologically active labile agent from the sustained release composition. Pharmaceutical compositions suitable for use in the method of the invention are also disclosed.Type: ApplicationFiled: October 8, 2003Publication date: June 24, 2004Applicant: Alkermes Controlled Therapeutics, Inc.Inventors: James R. Dasch, M. Gary I. Riley, Paul A. Burke, Susan A. Steitz-Abadi, Stephen E. Zale
-
Patent number: 6749866Abstract: The present invention relates to a composition for the modulated release of a biologically active agent. The composition comprises a biocompatible polymeric matrix, a biologically active agent which is dispersed within the polymeric matrix, and a metal cation component which is separately dispersed within the polymeric matrix, whereby the metal cation component modulates the release of the biologically active agent from the polymeric matrix. The present invention also relates to a method for modulating the release of a biologically active agent from a biocompatible polymeric matrix, comprising the steps of dissolving a biocompatible polymer in a solvent to form a polymer solution and also separately dispersing a metal cation component and a biologically active agent within the polymer solution.Type: GrantFiled: January 3, 2002Date of Patent: June 15, 2004Assignee: Alkermes Controlled Therapeutics, Inc.Inventors: Howard Bernstein, Yan Zhang, M. Amin Khan, Mark A. Tracy
-
Publication number: 20040108609Abstract: Copolymers of lactide and glycolide with high glycolide content. The average glycolate block length is less then about 3, which allows the copolymer to be soluble in slightly polar solvents such as methylene chloride.Type: ApplicationFiled: December 1, 2003Publication date: June 10, 2004Applicant: Alkermes Controlled Therapeutics Inc. IIInventor: Chiem V. Pham
-
Publication number: 20040099612Abstract: The present invention relates to a method and apparatus for filtering and drying a product. In a preferred embodiment, the apparatus comprises a container having a plurality of porous walls and a plurality of solid walls that divide the container into a plurality of product chambers, a plurality of vacuum chambers, and, preferably, a plurality of heat transfer chambers. Each product chamber shares at least one porous wall with an adjacent vacuum chamber. Each product chamber preferably shares at least one solid wall with an adjacent heat transfer chamber. According to the method of the present invention, a product is introduced into the product chambers, where the product is held while a substance is filtered from the product through the porous walls and the product is dried by reducing the pressure in the vacuum chambers and the product chambers.Type: ApplicationFiled: November 26, 2002Publication date: May 27, 2004Applicant: Alkermes Controlled Therapeutics, Inc.Inventors: Paul F. Herbert, Douglas M. Bissonnette, Gregory C. Troiano
-
Patent number: 6726860Abstract: The present invention relates to a method for forming microparticles of a material from microdroplets of a solution, wherein the solution comprises the material dissolved in a solvent. The method includes the steps of directing the microdroplets into a freezing zone, wherein the freezing zone is surrounded by a liquified gas, and wherein the microdroplets freeze. The frozen microdroplets are then mixed with a liquid non-solvent, whereby the solvent is extracted into the non-solvent, thereby forming the microparticles.Type: GrantFiled: December 6, 2001Date of Patent: April 27, 2004Assignee: Alkermes Controlled Therapeutics, Inc.Inventors: Paul F. Herbert, Michael S. Healy
-
Patent number: 6719970Abstract: The invention relates to an improved method for administering live cells to a patient and compositions useful in the method. The composition comprises live cells and biocompatible, biodegradable polymer microparticles. The cells and microparticles of the cell/microparticle composition can be contacted immediately prior to administration, or can be contacted in culture for a specified period of time prior to administration. In the method of the invention, an effective amount of the cell/microparticle composition is administered to a patient in need thereof by injection to a treatment site of the patient to provide a therapeutic effect in the patient. The therapeutic effect can be, for example, the formation of new tissue at the treatment site, or the production and secretion of a biologically active secretory molecule at the treatment site. The composition comprising lives cells and biocompatible, biodegradable polymer microparticles can further comprise a biologically active agent.Type: GrantFiled: July 10, 2000Date of Patent: April 13, 2004Assignees: Alkermes Controlled Therapeutics, Inc., University of MassachusettsInventors: Henry R. Costantino, Lawrence J. Bonassar, Mark A. Tracy
-
Patent number: 6713087Abstract: The present invention relates to a sustained release composition comprising micron particles of labile agent and a method of preparing and using the sustained release composition. The invention further relates to micron particles of a labile agent and a method of preparing the micron particles. The method of the invention for preparing a composition for the sustained release of a labile agent, comprises forming a suspension comprising the labile agent dispersed in a polymer solution comprising at least one biocompatible polymer and at least one polymer solvent. The suspension is then wet milled to achieve micron particles of the labile agent. The polymer solvent is then removed resulting in a solid polymer/labile agent matrix. The composition for sustained release of a labile agent is likewise prepared according to the method of the invention.Type: GrantFiled: July 18, 2002Date of Patent: March 30, 2004Assignee: Alkermes Controlled Therapeutics, Inc.Inventors: Mark A. Tracy, Kevin L. Ward, Warren E. Jaworowicz
-
Patent number: 6705757Abstract: Apparatus and method for preparing microparticles using in-line solvent extraction. An emulsion is formed by combining two phases in a static mixer. The emulsion is combined with an extraction liquid in a blending static mixer. The outflow of the blending static mixer is combined with additional extraction liquid. The additional extraction liquid and the outflow of the blending static mixer can be combined in a vessel, or through the use of a static mixer manifold that includes a plurality of static mixers.Type: GrantFiled: December 16, 2002Date of Patent: March 16, 2004Assignee: Alkermes Controlled Therapeutics, Inc. IIInventors: Shawn L. Lyons, Steven G. Wright
-
Patent number: 6703477Abstract: Copolymers of lactide and glycolide with high glycolide content. The average glycolate block length is less then about 3, which allows the copolymer to be soluble in slightly polar solvents such as methylene chloride.Type: GrantFiled: February 1, 2002Date of Patent: March 9, 2004Assignee: Alkermes Controlled Therapeutics, Inc. IIInventor: Chiem V. Pham
-
Publication number: 20040028733Abstract: This invention relates to sustained release compositions, and methods of forming and using said compositions, in particular for the sustained release of Follicle Stimulating Hormone (FSH). The sustained release compositions comprise a polymeric matrix of a biodegradable biocompatible polymer and stabilized FSH. The method of the invention for forming a sustained release composition includes, dissolving a biodegradable biocompatible polymer in a polymer solvent to form a polymer solution; adding biologically active stabilized FSH; removing the solvent; and solidifying the polymer to form a polymer matrix containing stabilized FSH dispersed therein. Also described is a method for providing a therapeutically effective amount of stabilized FSH in a patient in need of for a sustained period comprising administering to the patient a dose of the sustained release compositions of the invention.Type: ApplicationFiled: February 7, 2003Publication date: February 12, 2004Applicant: Alkermes Controlled Therapeutics, Inc.Inventors: Mark A. Tracy, Henry R. Costantino, Maria Figueiredo, Kevin L. Ward, David S. Scher
-
Publication number: 20030236192Abstract: The present invention relates to a method for the sustained release in vivo of a biologically active agent comprising administering to a subject in need of treatment an effective amount of a sustained release composition comprising a biocompatible polymer having the biologically active agent incorporated therein, and a bisphosphonate wherein the bisphosphonate compound is present in an amount sufficient to modify the release profile of the biologically active agent from the sustained release composition. Pharmaceutical compositions suitable for use in the method of the invention are also disclosed.Type: ApplicationFiled: March 25, 2003Publication date: December 25, 2003Applicant: Alkermes Controlled Therapeutics, Inc.Inventors: James R. Dasch, M. Gary I. Riley
-
Patent number: 6667061Abstract: Injectable compositions having improved injectability. The injectable compositions include microparticles suspended in an aqueous injection vehicle having a viscosity of at least 20 cp at 20° C. The increased viscosity of the injection vehicle that constitutes the fluid phase of the suspension significantly reduces in vivo injectability failures. The injectable compositions can be made by mixing dry microparticles with an aqueous injection vehicle to form a suspension, and then mixing the suspension with a viscosity enhancing agent to increase the viscosity of the fluid phase of the suspension to the desired level for improved injectability.Type: GrantFiled: September 30, 2002Date of Patent: December 23, 2003Assignee: Alkermes Controlled Therapeutics, Inc.Inventors: J. Michael Ramstack, M. Gary I. Riley, Stephen E. Zale, Joyce M. Hotz, Olufunmi L. Johnson
-
Publication number: 20030211164Abstract: A method for preparing microparticles having a selected polymer molecular weight. The hold time and temperature of a solution containing a nucleophilic compound and a polymer having a starting molecular weight are controlled in order to control the molecular weight of the polymer in the finished microparticle product. In this manner, a selected polymer molecular weight in the finished microparticle product can be achieved from a variety of starting material molecular weights.Type: ApplicationFiled: June 5, 2003Publication date: November 13, 2003Applicant: Alkermes Controlled Therapeutics Inc. IIInventors: Steven G. Wright, Michael E. Rickey, J. Michael Ramstack, Shawn L. Lyons, Joyce M. Hotz
-
Publication number: 20030203039Abstract: An improved method for preparing microparticles that exhibit controlled release of an effective amount of an active agent over an extended period of time. More particularly, a method is provided for preparing microparticles having a selected release profile for release of active agent contained in the microparticles. By adjusting the degree of drying that is performed during the preparation of the microparticles, the release profile can be controlled. By performing no intermediate drying, an initial burst and a substantially linear release profile is achieved. By performing substantially complete intermediate drying, an initial lag phase and a substantially sigmoidal release profile is achieved.Type: ApplicationFiled: May 12, 2003Publication date: October 30, 2003Applicant: Alkermes Controlled Therapeutics Inc. IIInventors: Shawn L. Lyons, J. Michael Ramstack, Steven G. Wright
-
Publication number: 20030165571Abstract: Sustained-release microparticle composition. The microparticle composition can be formulated to provide multi-phasic release. In one aspect, the composition includes microparticles having more than one rate of release. In another aspect, the composition includes microparticles that exhibit diffusional release and microparticles that exhibit biodegradation release.Type: ApplicationFiled: February 6, 2003Publication date: September 4, 2003Applicant: Alkermes Controlled Therapeutics Inc. IIInventors: Jean Mesens, Michael E. Rickey, Thomas J. Atkins
-
Publication number: 20030147967Abstract: Apparatus and method for preparing microparticles. An emulsion is formed by combining two phases in a static mixing assembly. The static mixing assembly preferably includes a preblending static mixer and a manifold. The emulsion flows out of the static mixing assembly into a quench liquid whereby droplets of the emulsion form microparticles. The residence time of the emulsion in the static mixing assembly is controlled to obtain a predetermined particle size distribution of the resulting microparticles.Type: ApplicationFiled: January 31, 2003Publication date: August 7, 2003Applicant: Alkermes Controlled Therapeutics Inc. IIInventors: Shawn L. Lyons, Steven G. Wright
-
Publication number: 20030143279Abstract: A method for preparing microparticles having a selected polymer molecular weight. The hold time and temperature of a solution containing a nucleophilic compound and a polymer having a starting molecular weight are controlled in order to control the molecular weight of the polymer in the finished microparticle product. In this manner, a selected polymer molecular weight in the finished microparticle product can be achieved from a variety of starting material molecular weights.Type: ApplicationFiled: January 28, 2003Publication date: July 31, 2003Applicant: Alkermes Controlled Therapeutics Inc. IIInventors: Steven G. Wright, Michael E. Rickey, J. Michael Ramstack, Shawn L. Lyons, Joyce M. Hotz